We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
Cap. Flow
+$79.7M
Cap. Flow %
14.07%
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.7M
2
SNY icon
Sanofi
SNY
+$9.45M
3
CCXI icon
ChemoCentryx, Inc.
CCXI
+$9.01M
4
PNTG icon
Pennant Group
PNTG
+$8.5M
5
MDCO
Medicines Co
MDCO
+$7.63M

Top Sells

Rank Stock Value
1
AMRN icon
Amarin Corp
AMRN
+$7.86M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.4M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.78M
4
DXCM icon
DexCom
DXCM
+$6.17M
5
ABMD
Abiomed Inc
ABMD
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 82.4%
2 Miscellaneous 13.14%
3 Real Estate 1.69%
4 Communication Services 1.29%
5 Industrials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$805B
$51.5M 9.09%
+160,000
New +$49.3M
2019 Q4
0 quarters
GSK icon
2
GSK
GSK
$99.3B
$48.6M 8.58%
818,468
+32,000
+4% +$1.78M
2018 Q1
7 quarters
ENSG icon
3
The Ensign Group
ENSG
$10.3B
$30.7M 5.42%
676,058
+48,903
+8% +$2.06M
2017 Q4
8 quarters
DHR icon
4
Danaher
DHR
$161B
$30.3M 5.35%
222,337
+20,759
+10% +$2.62M
2018 Q3
5 quarters
ASND icon
5
Ascendis Pharma A/S
ASND
$14.8B
$28.2M 4.98%
202,894
-33,498
-14% -$3.72M
2017 Q4
8 quarters
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
$25.8M 4.56%
495,645
-148,173
-23% -$6.78M
2017 Q4
8 quarters
SNY icon
7
Sanofi
SNY
$96.3B
$22.2M 3.92%
441,661
+201,661
+84% +$9.45M
2017 Q4
8 quarters
AMRN icon
8
CALL
Amarin Corp
AMRN
$238M
$21.3M 3.76%
49,710
+41,655
+517% +$15.8M
2019 Q3
1 quarter
CCXI icon
9
DELISTED
ChemoCentryx, Inc.
CCXI
$20.3M 3.58%
+513,189
New +$9.01M
2019 Q4
0 quarters
AMRN icon
10
Amarin Corp
AMRN
$238M
$19.6M 3.47%
45,780
-20,705
-31% -$7.86M
2018 Q1
7 quarters
BOLD icon
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$18.3M 3.23%
305,726
+52,000
+20% +$1.95M
2019 Q2
2 quarters
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$1.99B
$16.9M 2.99%
4,904,460
+4,250,000
+649% +$10.7M
2017 Q4
8 quarters
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$127B
$16M 2.82%
73,009
+22,100
+43% +$4.47M
2017 Q4
8 quarters
NVST icon
14
Envista
NVST
$3.7B
$15M 2.65%
506,678
+188,678
+59% +$5.37M
2019 Q3
1 quarter
PNTG icon
15
Pennant Group
PNTG
$1.46B
$12.3M 2.17%
+371,193
New +$8.5M
2019 Q4
0 quarters
MDCO
16
DELISTED
Medicines Co
MDCO
$9.71M 1.72%
+114,358
New +$7.63M
2019 Q4
0 quarters
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.81B
$9.68M 1.71%
+75,000
New +$7.57M
2019 Q4
0 quarters
APLS icon
18
DELISTED
Apellis Pharmaceuticals
APLS
$9.5M 1.68%
310,409
+230,900
+290% +$6.39M
2018 Q2
6 quarters
TGTX icon
19
TG Therapeutics
TGTX
$8.31B
$8.62M 1.52%
776,323
+2,822
+0.4% +$21.5K
2018 Q1
7 quarters
DCPH icon
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8.01M 1.42%
128,748
+106,748
+485% +$5.07M
2018 Q4
4 quarters
MODN icon
21
DELISTED
MODEL N, INC.
MODN
$7.28M 1.29%
207,615
+86,920
+72% +$2.65M
2019 Q3
1 quarter
FATE icon
22
Fate Therapeutics
FATE
$217M
$7.06M 1.25%
360,656
+220,000
+156% +$3.49M
2018 Q4
4 quarters
AZN icon
23
AstraZeneca
AZN
$255B
$7.01M 1.24%
+70,281
New +$6.62M
2019 Q4
0 quarters
BLUE icon
24
DELISTED
bluebird bio
BLUE
$6.44M 1.14%
+5,666
New +$6.16M
2019 Q4
0 quarters
RDUS icon
25
DELISTED
Radius Health, Inc.
RDUS
$6.43M 1.14%
318,811
-25,887
-8% -$629K
2017 Q4
8 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.

  • Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
  • Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
  • Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
  • Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
  • Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
  • Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
  • Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.

Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.